Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR1 amp Ponatinib lung squamous cell carcinoma sensitive detail...
Unknown unknown Cisplatin + Gemcitabine + Necitumumab lung squamous cell carcinoma not applicable detail...
Unknown unknown Cisplatin + Necitumumab + Pemetrexed lung squamous cell carcinoma not applicable detail...
PTEN loss AZD8186 lung squamous cell carcinoma predicted - sensitive detail...
PDGFRA amp Dasatinib lung squamous cell carcinoma sensitive detail...
PDGFRA amp Imatinib lung squamous cell carcinoma sensitive detail...
KRAS mutant Trametinib lung squamous cell carcinoma sensitive detail...
ERBB2 amp Gefitinib lung squamous cell carcinoma resistant detail...
FGFR1 amp Dovitinib lung squamous cell carcinoma no benefit detail...
FGFR1 amp RO4987655 lung squamous cell carcinoma no benefit detail...
FGFR1 amp RO5126766 lung squamous cell carcinoma no benefit detail...
FGFR1 amp Selumetinib lung squamous cell carcinoma no benefit detail...
HRAS Q61L Selumetinib lung squamous cell carcinoma sensitive detail...
HRAS Q61L Buparlisib lung squamous cell carcinoma no benefit detail...
HRAS Q61L Everolimus + Selumetinib lung squamous cell carcinoma sensitive detail...
HRAS Q61L Binimetinib + Everolimus lung squamous cell carcinoma sensitive detail...
HRAS Q61L AZD8055 + Binimetinib lung squamous cell carcinoma sensitive detail...
MET over exp EMD 1214063 lung squamous cell carcinoma sensitive detail...
MET del exon14 Capmatinib lung squamous cell carcinoma predicted - sensitive detail...
FGFR1 amp BGJ398 lung squamous cell carcinoma sensitive detail...
PTEN negative Buparlisib lung squamous cell carcinoma sensitive detail...
MET del exon14 MET D1228N Crizotinib lung squamous cell carcinoma predicted - resistant detail...
Unknown unknown Docetaxel + Trametinib lung squamous cell carcinoma not applicable detail...
FGFR1 amp AZD4547 + Buparlisib lung squamous cell carcinoma sensitive detail...
FGFR3 positive Rogaratinib lung squamous cell carcinoma predicted - sensitive detail...
FGFR1 amp AZD4547 lung squamous cell carcinoma no benefit detail...
FGFR1 amp MET amp BGJ398 lung squamous cell carcinoma predicted - resistant detail...
MET amp SCC244 lung squamous cell carcinoma sensitive detail...
ERBB2 mutant Afatinib lung squamous cell carcinoma predicted - sensitive detail...
ERBB4 mutant Afatinib lung squamous cell carcinoma predicted - sensitive detail...
Unknown unknown Prexasertib lung squamous cell carcinoma not applicable detail...
Unknown unknown Carboplatin + Paclitaxel + Pembrolizumab lung squamous cell carcinoma not applicable detail...
Unknown unknown Carboplatin + Nab-paclitaxel + Pembrolizumab lung squamous cell carcinoma not applicable detail...
PTEN loss Buparlisib lung squamous cell carcinoma no benefit detail...
ERBB2 S310Y Afatinib lung squamous cell carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01351103 Phase I LGK974 LGK974 + PDR001 A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Recruiting
NCT01737502 Phase Ib/II Auranofin + Sirolimus Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer Recruiting
NCT01741727 Phase II Depatuxizumab mafodotin A Study of ABT-414 in Subjects With Solid Tumors Completed
NCT01820325 Phase II Buparlisib Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer Terminated
NCT01877811 Phase Ib/II RXDX-105 CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2 Completed
NCT01948141 Phase II Nintedanib Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens Completed
NCT01976741 Phase I Rogaratinib Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor Active, not recruiting
NCT02240238 Phase Ib/II Gemcitabine + NC-6004 Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer Active, not recruiting
NCT02393248 Phase Ib/II Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib INCMGA00012 + Pemigatinib Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Recruiting
NCT02403895 Phase II Vistusertib Paclitaxel AZD2014 and Weekly Paclitaxel in Squamous NSCLC Terminated
NCT02417701 Phase II Sapanisertib TORC1/2 Inhibitor MLN0128 in Treating Patients With Stage IV or Recurrent Lung Cancer Recruiting
NCT02443337 Phase II Necitumumab LY3023414 A Study of LY3023414 and Necitumumab in Squamous Lung Cancer Terminated
NCT02444793 Phase I Mogamulizumab + Utomilumab A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors Terminated
NCT02513563 Phase II Carboplatin + Paclitaxel Adavosertib AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer Recruiting
NCT02536495 Phase Ib/II Docetaxel Selinexor Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer Withdrawn
NCT02785913 Phase II Taselisib Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Active, not recruiting
NCT02785939 Phase II Palbociclib Lung-MAP: Palbociclib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Active, not recruiting
NCT02785952 Phase III Nivolumab Ipilimumab + Nivolumab Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Recruiting
NCT02924233 Phase Ib/II Nivolumab + SYM004 Nivolumab Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer Withdrawn
NCT03065062 Phase I Gedatolisib + Palbociclib Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors Recruiting
NCT03157089 Phase II Afatinib + Pembrolizumab Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung (LUX-Lung IO) Active, not recruiting
NCT03178552 Phase II Entrectinib Carboplatin + Cisplatin + Gemcitabine Atezolizumab Carboplatin + Cisplatin + Pemetrexed Alectinib A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST) Recruiting
NCT03234712 Phase I ABBV-321 A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands Recruiting
NCT03261947 Phase II TAK-931 A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors Recruiting
NCT03377556 Phase II Talazoparib Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer Recruiting
NCT03441100 Phase I Cyclophosphamide + Fludarabine Aldesleukin IMA202 TCR-engineered T Cells in NSCLC and HCC Patients Recruiting
NCT03476681 Phase I NEO-201 QUILT-3.017: Study of NEO-201 in Solid Tumors Recruiting
NCT03574753 Phase II Telisotuzumab vedotin Lung-MAP S1400K: c-MET Positive Active, not recruiting
NCT03811652 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors Recruiting